+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Graft Versus Host Disease Treatment Market by Treatment Class, Application Stage, Route of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Graft Versus Host Disease Treatment Market by Treatment Class, Application Stage, Route of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Graft Versus Host Disease Treatment Market by Treatment Class, Application Stage, Route of Administration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5532915
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Graft Versus Host Disease Treatment Market grew from USD 2.06 billion in 2024 to USD 2.28 billion in 2025. It is expected to continue growing at a CAGR of 10.55%, reaching USD 3.77 billion by 2030.

Unveiling the Frontiers of Graft Versus Host Disease Management

Graft versus host disease represents one of the most pressing challenges in the realm of allogeneic transplantation. As the number of patients undergoing stem cell and bone marrow transplants grows, so does the imperative to manage immune-mediated complications with precision and efficacy. Therapy for this condition has historically relied on broad immunosuppression, yet emerging scientific advances are shifting the paradigm toward targeted immunomodulation.

This executive summary provides a concise yet thorough overview of the current treatment landscape, transformative trends, regulatory dynamics, and strategic considerations for stakeholders. It distills complex developments into actionable intelligence, enabling decision-makers to navigate evolving modalities, supply chain pressures, and competitive forces with confidence.

Disruptive Innovations Reshaping the Therapeutic Landscape

Over recent years the therapeutic landscape has experienced a profound metamorphosis, driven by a wave of novel agents and precision-focused strategies. Targeted molecules that once lived on the fringes have moved to center stage, reducing off-target toxicity while maintaining robust immunosuppressive profiles. Next-generation JAK inhibitors, building on the foundation of their predecessors, offer refined selectivity that translates into improved safety and tolerability.

Monoclonal antibody therapies have also evolved, with designers tailoring their mechanisms toward CD52, interleukin-2 receptor, and TNF pathways. These agents complement traditional corticosteroids and calcineurin inhibitors by providing clinicians with the flexibility to assemble combination regimens that address varying severities and stages of disease. In parallel, digital health applications and biomarker-driven protocols are enabling more nuanced patient monitoring and personalized dosing trajectories, marking a decisive shift from one-size-fits-all to precision medicine in this field.

Navigating the Ripple Effects of 2025 US Tariffs

The imposition of new US tariff measures in 2025 has reverberated across global supply chains and procurement strategies. Pharmaceutical companies now face elevated import costs for key active pharmaceutical ingredients and finished biologics, which in turn pressures downward on profit margins and compels a re-examination of pricing frameworks. Some manufacturers have begun to seek alternative sourcing arrangements or to localize production to mitigate these added expenses.

Meanwhile, regulatory authorities are scrambling to balance trade policies with patient needs, recognizing that prolonged delays in product availability can undermine clinical outcomes. Strategic alliances between multinational corporations and regional suppliers are emerging as a pragmatic response, ensuring that vital therapies continue to reach the bedside without undue disruption. This tariff environment underscores the importance of resilient logistics and proactive policy engagement for sustaining access to critical graft versus host disease treatments.

Decoding Market Dynamics Through Precise Segmentation

A granular examination of treatment class reveals that the market is anchored by calcineurin inhibitors and corticosteroids, which maintain their role as foundational therapies. However, the ascending trajectory of JAK inhibitors-categorized into first-generation and next-generation variants-reflects a shift in prescriber preferences towards agents offering better tolerability and tailored immunomodulation. Monoclonal antibody approaches further diversify the arsenal, with distinct targeting of CD52, IL-2 receptor pathways, and TNF signaling.

Beyond pharmacological classes, application stage segmentation differentiates first-line interventions from salvage therapy and second-line regimens, each demanding unique efficacy and safety trade-offs. Divergent administration routes, spanning intravenous infusions to oral and subcutaneous formulations, cater to both inpatient and outpatient settings. End users range from ambulatory care centers through hospitals and specialized clinics, where care protocols and reimbursement structures vary. Finally, distribution channels extend from traditional hospital pharmacies to online and retail outlets, reflecting evolving procurement models and patient access preferences.

Regional Pulse Across Major Global Markets

In the Americas, robust research infrastructures, generous reimbursement frameworks, and early adoption of innovative therapies position this region at the forefront of clinical advancement. Collaborative networks between academic centers and industry fuel a steady pipeline of trials that shape global practice guidelines. Conversely, Europe, the Middle East and Africa demonstrate growing harmonization of regulatory processes alongside pockets of variability in healthcare funding and market access, prompting stakeholders to adapt launch strategies accordingly.

Asia-Pacific exhibits a dynamic blend of mature and emerging markets, where capacity expansions and strategic partnerships with local manufacturers enhance affordability. Demographic shifts and rising healthcare investment drive a heightened focus on both inpatient infusion centers and decentralized care models. Across all regions, a shared emphasis on evidence generation and real-world data continues to influence reimbursement negotiations and formulary decisions, shaping the global deployment of graft versus host disease treatments.

Profiles of Leading Players Driving Progress

Leading pharmaceutical and biotech companies are actively reshaping the competitive terrain through targeted acquisitions, collaborative research agreements, and portfolio optimization. Industry stalwarts renowned for their calcineurin inhibitor platforms are broadening their pipelines to include next-generation JAK inhibitors, while biotech innovators focus on monoclonal antibody advancements and biomarker-informed patient stratification.

Strategic partnerships between multinational corporations and specialized developers are accelerating clinical development timelines, enabling faster progression from proof-of-concept to regulatory submission. Additionally, contract manufacturing organizations are playing an increasingly pivotal role in scaling production of complex biologics and cell-based therapies. This collective endeavor underscores a market ethos centered on agility, precision, and patient-centric innovation.

Strategic Imperatives for Industry Stakeholders

Industry leaders should prioritize investment in targeted immunomodulators that offer differentiated safety and efficacy profiles, securing a competitive edge through proprietary molecule development. Concurrently, establishing resilient supply chains with diversified sourcing and production capabilities will mitigate geopolitical and tariff-related disruptions. Engaging payers and health authorities early in the development cycle ensures clarity on evidence requirements for coverage decisions, accelerating time to market.

Furthermore, cultivating partnerships with emerging biotech firms and academic institutions can unlock novel modalities and expand therapeutic horizons. Embracing real-world evidence generation through digital health and patient registries will strengthen value propositions and support outcomes-based agreements. Finally, exploring growth opportunities in underpenetrated regions by tailoring access models to local healthcare infrastructures can drive sustainable volume growth.

Transparent and Rigorous Research Framework

Our analysis integrates insights from primary interviews with key opinion leaders, clinical investigators, payers, and manufacturing experts. Secondary data sources include regulatory filings, peer-reviewed publications, clinical trial registries, and proprietary commercial intelligence databases. We apply rigorous triangulation methodologies to reconcile divergent data points, ensuring consistency and validity across multiple inputs.

Quantitative metrics undergo stringent quality assurance processes, while qualitative themes are validated through expert review panels. All findings are contextualized within current regulatory frameworks and reimbursement landscapes to deliver a holistic view. This transparent framework underpins the credibility and actionable nature of our conclusions.

Synthesis of Insights and Pathways Forward

The treatment paradigm for graft versus host disease is rapidly evolving, driven by breakthroughs in targeted therapeutics, precision medicine, and supply chain resilience. Stakeholders must navigate tariff-induced cost pressures while capitalizing on the differentiated attributes of next-generation agents and monoclonal antibodies. Regional disparities in regulatory and reimbursement environments necessitate tailored market entry and growth tactics.

By integrating segmentation insights, regional nuances, and competitive intelligence, decision-makers can articulate strategies that balance innovation with operational efficiency. Collaboration between industry, clinical leaders, and payers will be essential for sustaining access and improving patient outcomes in this complex care continuum.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Class
    • Calcineurin Inhibitors
    • Corticosteroids
    • JAK Inhibitors
      • First Generation
      • Next Generation
    • Monoclonal Antibodies
      • Anti CD52
      • Anti IL-2 Receptor
      • Anti TNF
  • Application Stage
    • First Line
    • Salvage Therapy
    • Second Line
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • End User
    • Ambulatory Care Centers
    • Hospitals
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Incyte Corporation
  • AbbVie Inc.
  • Kadmon Holdings, Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Mesoblast Limited
  • Pfizer Inc.
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd
  • Mallinckrodt Pharmaceuticals Ireland Designated Activity Company

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Graft Versus Host Disease Treatment Market, by Treatment Class
8.1. Introduction
8.2. Calcineurin Inhibitors
8.3. Corticosteroids
8.4. JAK Inhibitors
8.4.1. First Generation
8.4.2. Next Generation
8.5. Monoclonal Antibodies
8.5.1. Anti CD52
8.5.2. Anti IL-2 Receptor
8.5.3. Anti TNF
9. Graft Versus Host Disease Treatment Market, by Application Stage
9.1. Introduction
9.2. First Line
9.3. Salvage Therapy
9.4. Second Line
10. Graft Versus Host Disease Treatment Market, by Route of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Graft Versus Host Disease Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Hospitals
11.4. Specialty Clinics
12. Graft Versus Host Disease Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Graft Versus Host Disease Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Graft Versus Host Disease Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Graft Versus Host Disease Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Incyte Corporation
16.3.2. AbbVie Inc.
16.3.3. Kadmon Holdings, Inc.
16.3.4. Novartis AG
16.3.5. Bristol-Myers Squibb Company
16.3.6. Mesoblast Limited
16.3.7. Pfizer Inc.
16.3.8. Sanofi S.A.
16.3.9. F. Hoffmann-La Roche Ltd
16.3.10. Mallinckrodt Pharmaceuticals Ireland Designated Activity Company
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GRAFT VERSUS HOST DISEASE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. GRAFT VERSUS HOST DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. GRAFT VERSUS HOST DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ANTI CD52, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ANTI IL-2 RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ANTI TNF, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 51. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 53. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 54. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 60. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 96. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 97. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 101. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 103. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 104. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 115. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 117. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 118. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 122. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 124. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 125. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 150. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 152. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 153. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 164. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 166. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 167. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 173. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 192. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 194. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 195. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 199. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 201. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 202. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 215. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 220. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 222. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 223. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 241. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 242. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 244. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 245. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 249. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 251. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 252. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 256. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 257. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 258. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 259. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY APPLICATION STAGE, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2030 (USD MILLION)
TABLE 284. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 285. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 286. THAILAND GRA

Companies Mentioned

The companies profiled in this Graft Versus Host Disease Treatment market report include:
  • Incyte Corporation
  • AbbVie Inc.
  • Kadmon Holdings, Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Mesoblast Limited
  • Pfizer Inc.
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd
  • Mallinckrodt Pharmaceuticals Ireland Designated Activity Company

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.28 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.77 Billion
Compound Annual Growth Rate10.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Steroid Refactory Acute Graft-Versus-Host Disease (GVHD) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Steroid Refactory Acute Graft-Versus-Host Disease (GVHD) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Chronic Graft Versus Host Disease (cGvHD) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Graft Versus Host Disease (cGvHD) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Steroid Refractory Acute Graft Versus Host Disease Market - Product Image

Steroid Refractory Acute Graft Versus Host Disease Market

  • Report
  • 250 Pages
  • Global
From
Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Graft Versus Host Disease (GVHD) Treatment Market Report 2025 - Product Image

Graft Versus Host Disease (GVHD) Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Graft Versus Host Disease Drug Market

Graft Versus Host Disease (GVHD) is a type of immune disorder that occurs when transplanted donor cells attack the recipient's body. It is a common complication of bone marrow and stem cell transplants. Treatment for GVHD typically involves immunosuppressive drugs, such as corticosteroids, calcineurin inhibitors, and monoclonal antibodies. These drugs are used to reduce inflammation and suppress the immune system, allowing the body to accept the donor cells. The GVHD drug market is a rapidly growing segment of the immune disorder drug market. It is driven by the increasing prevalence of GVHD, as well as the development of new drugs and treatments. The market is expected to continue to grow in the coming years, as more treatments become available and the demand for GVHD drugs increases. Some of the major companies in the GVHD drug market include Novartis, Celgene, Gilead Sciences, and Bristol-Myers Squibb. These companies are involved in the development and marketing of GVHD drugs, as well as other immune disorder drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.